Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: The SOPHIA study

Pharmacogenomics

Volumn 15, Issue 13, 2014, Pages 1643-1652

  Frau, Francesca ^a,b,c   Zaninello, Roberta ^a   Salvi, Erika ^b,c   Ortu, Maria Francesca ^a   Braga, Daniele ^b,c   Velayutham, Dinesh ^b,c   Argiolas, Giuseppe ^a   Fresu, Giovanni ^a   Troffa, Chiara ^a   Bulla, Emanuela ^d   Bulla, Patrizia ^a   Pitzoi, Silvia ^a   Piras, Daniela Antonella ^a   Glorioso, Valeria ^a   Chittani, Martina ^b,c   Bernini, Giampaolo ^e   Bardini, Michele ^e   Fallo, Francesco ^f   Malatino, Lorenzo ^g   Stancanelli, Benedetta ^g   Regolisti, Giuseppe ^h   Ferri, Claudio ⁱ   Desideri, Giovanbattista ⁱ   Scioli, Giuseppe Antonio ^j   Galletti, Ferruccio ^k   Sciacqua, Angela ^l   Perticone, Francesco ^l   Degli Esposti, Ezio ^m   Sturani, Alessandra ⁿ   Semplicini, Andrea ^o   Veglio, Franco ^p   Mulatero, Paolo ^p   Williams, Tracy A ^p   Lanzani, Chiara ^q   Hiltunen, Timo P ^r   Kontula, Kimmo ^r   Boerwinkle, Eric ^s   Turner, Stephen T ^t   Manunta, Paolo ^q   Barlassina, Cristina ^b,c   Cusi, Daniele ^b,c   Glorioso, Nicola ^a   more..

^a UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Filarete Foundation   (Italy)

^d Neurology Unit   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h UNIVERSITY OF PARMA   (Italy)

ⁱ UNIVERSITY OF L'AQUILA   (Italy)

^j F Veneziale Hospital   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^m Economics and Outcomes Research   (Italy)

ⁿ Ospedale Provinciale S Maria delle Croci   (Italy)

^o SS Giovanni e Paolo Hospital   (Italy)

^p UNIVERSITY OF TURIN   (Italy)

^q SAN RAFFAELE HOSPITAL   (Italy)

^r UNIVERSITY OF HELSINKI   (Finland)

^s UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^t MAYO CLINIC   (United States)

more..

Author keywords

angiotensin II receptor blockers; genome wide association analysis; genomics; hypertension; losartan; pharmacogenomics

Indexed keywords

HYDROCHLOROTHIAZIDE; LOSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE I; CAMK1D PROTEIN, HUMAN;

ADULT; ARTICLE; CAMK1D GENE; CONTROLLED STUDY; COUGHING; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; GENE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACOGENETICS; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG EFFECTS; GENETICS; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84913601524     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.119     Document Type: Article

References (31)

1. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of treatment by crossover rotation of four major classes. Lancet 353(9169), 2008-2013 (1999).
2. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
3. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Hypertension: Pathophysiology, Diagnosis and Management. Laragh JH, Brenner BM (Eds.) Raven Press, NY, USA, 81-100 (1990).
4. Butler H, Ragoussis J. Bead-array based technology. Methods Mol. Biol. 439, 53-74 (2008).
5. Glorioso N, Argiolas G, Filigheddu F et al. Study group on Cardiovascular Pharmacogenomics of Italian Society of Hypertension. Conceptual basis and methodology of the SOPHIA study. Pharmacogenomics 8(11), 1497-1509 (2007).
6. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension 59(6), 1204-1211 (2012).
7. Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am. J. Hypertens. 20(3), 311-318 (2007).
8. Lanzani C, Citterio L, Glorioso N et al. Adducin-and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Sci. Transl. Med. 2(59), 59-87 (2010).
9. Salvi E, Kutalik Z, Glorioso N et al. Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension 59(2), 248-255 (2012).
10. InterOmics Project. www.interomics.eu
11. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet. Epidemiol. 34(8), 816-834 (2010).
12. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality control in genetic case-control association studies. Nat. Protoc. 5(9), 1564-1573 (2010).
13. Price AL, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904-909 (2006).
14. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet. 2, 2074-2093 (2006).
15. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559-575 (2007).
16. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol. Cell Endocrinol. 350, 151-162 (2012)
17. Condon JC, Pezzi V, Drummond BM, Yin S, Rainey WE. Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase. Endocrinology 143(9), 3651-3657 (2002).
18. Spät A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 84, 489-539 (2004).
19. Sakagami H, Kamata A, Nishimura H et al. Prominent expression and activity-dependent nuclear translocation of Ca2+/calmodulin-dependent protein kinase Idelta in hippocampal neurons. Eur. J. Neurosci. 22(11), 2697-2707 (2005).
20. Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat. Rev. Endocrinol. 9, 104-112 (2013).
21. Beuschlein F, Boulkroun S, Osswald A et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat. Genet. 45, 440-444 (2013).
22. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 351(1), 33-41 (2004).
23. Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment: Medical Research Council Working Party on Mild Hypertension. Br. Med. J. 11, 988-992 (1986).
24. Filigheddu F, Troffa C, Glorioso N. Pharmacogenomics of essential hypertension: are we going the right way? Cardiovasc. Hematol Agents Med. Chem. 4(1), 7-15 (2006).
25. Kurland L, Melhus H, Karlsson J et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J. Hypertens. 19(10), 1783-1787 (2001).
26. Nordestgaard BG, Kontula K, Benn M et al. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet. Genomics 20(2), 77-85 (2010).
27. Suonsyrjä T, Hannila-Handelberg T, Fodstad H, Donner K, Kontula K, Hiltunen TP. Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. Am. J. Hypertens. 22(2), 169-175 (2009).
28. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur. J. Pharmacol. 445(1-2), 151-152 (2002).
29. Donner KM, Hiltunen TP, Hannila-Handelberg T, Suonsyrjä T, Kontula K. STK39 variation predicts ambulatory blood pressure response to losartan in hypertensive men. Hypertension Res. 35, 107 (2012).
30. Frau F, Citterio L, Ortu MF, Zaninello R. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension 61, e5 (2013).
31. Kamide K, Asayama K, Katsuya T et al. Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study. Pharmacogenomics 14, 1709-1721 (2013).